Stock CTXR CITIUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Citius Pharmaceuticals, Inc.

Equities

CTXR

US17322U2078

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
0.692 USD +4.09% Intraday chart for Citius Pharmaceuticals, Inc. -9.81% -8.53%
Apr. 26 Citius Pharmaceuticals Launches $15 Million Offering MT
Apr. 11 Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
PR
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
PR
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
PR
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
PR
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
PR
Citius Pharmaceuticals to Participate In Upcoming BIO CEO and Sidoti Investor Conferences
AQ
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration
PR
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
PR
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
AQ
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
PR
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
PR
Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors
PR
Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of Its Mino-Lok Therapeutic To Salvage Catheters
AQ
Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters
PR
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
PR
Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023
PR
Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR in Combination with Checkpoint Inhibitor
AQ
Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor
PR
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
PR
Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CTXR Stock
  4. News Citius Pharmaceuticals, Inc.
  5. Press Releases